Based on the predicted outcomes of network pharmacology and molecular docking, it has been determined that luteolin’s therapeutic effect on NSCLC involves core targets such as TP53, EGFR, and AKT1, closely associating with the PI3K-Akt signaling pathway. The gene discussed is PIK3CG; the disease is non-small cell lung carcinoma.